ClinicalTrials.gg
CompletedNCT04841096Updated Jun 10, 2025

Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure

A Phase 3 interventional study of A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg) and B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg) in Type 2 Diabetes, sponsored by Laboratorios Silanes S.A. de C.V.. Completed at 5 sites in Mexico. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Laboratorios Silanes S.A. de C.V. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies testing glimepiride in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. glimepiride · Diabetes Mellitus, Type 2.

Enrollment
28th of 52
162 · median 169
Started
2023
the only one that year
Phase 3
18 of 52
1 open now
Registered
50th of 52
by date
Lead sponsor
2 of 52
Laboratorios Silanes S.A. de C.V.

Among the 52 studies testing glimepiride in Diabetes Mellitus, Type 2, this one is the 28th largest by enrollment, is the only one that started in 2023, is one of 18 in phase 3, and was the 50th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 52 studies testing glimepiride in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About glimepiride

glimepiride: first FDA approval 1995 (AMARYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing glimepiride in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Phase IIIb, randomized, multicenter, double-blind, prospective study to evaluate the efficacy and safety of a daily fixed-dose combination of glimepiride / vildagliptin / metformin in patients with type 2 diabetes with a history of dual treatment failure and combined or individual oral antidiabetics with SGLT2 / Metformin, Biguanide / Sulfonylurea, Sulfonylurea / iDPP4 or Biguanide / iDPP4. To evaluate the changes in the percentage of HbA1c at 3 and 6 months with regard to their baseline measurement.

Read the detailed description

To achieve glycemic control goals, a combination of medications with complementary mechanisms of action, with fasting and postprandial effects, may be required to achieve and maintain clinically acceptable glycemic control in some patients. A fixed combination of two or more therapeutic agents with complementary mechanisms of action makes it possible to optimize compliance and adherence to treatment among patients with T2D because it is administered once a day with the same efficacy of the separate components, but with fewer gastrointestinal effects. This is reflected in a reduction in HA1c and a lower evolution to long-term complications of T2D. Phase IIIb, randomized, multicenter, double-blind, prospective study to evaluate the efficacy and safety of a daily fixed-dose combination of glimepiride / vildagliptin / metformin in patients with type 2 diabetes with a history of dual treatment failure and combined or individual oral antidiabetics with SGLT2 / Metformin, Biguanide / Sulfonylurea, Sulfonylurea / iDPP4 or Biguanide / iDPP4.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Type 2 diabetes
  • Combine therapy
  • Hypoglycemic agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female.
  • Age >18 years old at the beginning of the study.
  • Diagnosis of type 2 diabetes prior to the start of the study.
  • Therapeutic failure to a dual treatment with SGLT2 / Metformin, Biguanide / Sulfonylurea, Sulfonylurea / iDPP4, Biguanide / iDPP4.
  • ≥ 7.5% and ≤ 11% during screening tests.
  • Women of using a method (barrier, oral hormonal, injectable, subdermal) or naturally or surgically sterile in menopause.
  • Subject agree to participate in the study and give in writing.

Exclusion criteria

Exclusion Criteria:

  • The drug is for medical reasons.
  • History of Type 1 Diabetes Mellitus.
  • History of metabolic complications such as ketoacidosis or nonketotic hyperosmolar state.
  • History of gastric bariatric surgery or gastric band in the last year.
  • History of drug or alcohol abuse in the past year.
  • \<20 kg/m2 and >40 kg/m2.
  • Acute or severe renal dysfunction (glomerular filtration \<30 ml / min / 1.72 m2).
  • History of chronic liver disease or and / or AST ≥3 times the normal upper limit and / or Total > 2.5 times the , or GGT ≥3 times the upper limit of normal.
  • Pregnant and / or lactating women.
  • The patient is participating in another clinical study involving an treatment or participated in one in the previous 4 weeks.
  • At medical criteria, a disease that affects the prognosis and prevents outpatient management, for example, but not restricted to: end-stage cancer, kidney, heart, respiratory or liver failure, mental illness, with scheduled surgical or hospital procedures.
  • Be a patient with a working relationship with the main researcher or the research center or deprived of liberty.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Group A1: Glimepiride (1mg) / Vildagliptin (50mg) / Metformin (500mg).

    Tablets, orally, once a day. Initial dose for the first 45 days of intervention.

    Drug: A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)

  • Experimental
    Group B1: Glimepiride (1mg) / Vildagliptin (50mg) / Metformin (500mg)

    Tablets, orally, once a day. Initial dose for the first 45 days of intervention.

    Drug: B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)

  • Experimental
    Group A2: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)

    Tablets, orally, once a day. Dose escalation if the patients meets established criteria.

    Drug: (A2) Glimepiride/Vildagliptin/Metformin

  • Experimental
    Group B2: Glimepiride (4mg) / Vildagliptin (50mg) / Metformin (1000mg)

    Tablets, orally, once a day. Dose escalation if the patients meets established criteria.

    Drug: (B2) Glimepiride/Vildagliptin/Metformin

Interventions

  • DrugA1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)

    Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.

    Also known as: (A1) Glimepiride/Vildagliptin/Metformin

  • DrugB2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)

    take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.

    Also known as: (B1) Glimepiride/Vildagliptin/Metformin

  • Drug(A2) Glimepiride/Vildagliptin/Metformin

    Drug pages: Glimepiride · Vildagliptin · Metformin

    Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.

    Also known as: A2=Glimepiride / Vildagliptin / Metformin (2 mg/ 50 mg/ 1000 mg)

  • Drug(B2) Glimepiride/Vildagliptin/Metformin

    Drug pages: Glimepiride · Vildagliptin · Metformin

    Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.

    Also known as: B2=Glimepiride / Vildagliptin / Metformin (4 mg/ 50 mg/ 1000 mg)

06

What researchers measure

Primary outcomes

  1. Compare changes in HbA1

    Mean change in HbA1c

    Time frame: baseline, 3 and 6 months of treatment

  2. Proportion of patients who change their HbA1c concentration

    Proportion of patients who change their HbA1c by at least 1 percent

    Time frame: baseline, 3 and 6 months of treatment

  3. Mean difference change between groups in HbA1c concentration

    Difference greater than 0.3 between group A and B HbA1c concentration

    Time frame: baseline, 3 and 6 months of treatment

Secondary outcomes

  1. Mean glucose change

    Compare changes in glucose between baseline, 3 and 6 months of treatment

    Time frame: baseline, 3 and 6 months of treatment

  2. Incidence of adverse events and reactions

    Description of al the adverse events and reactions presented during the study

    Time frame: baseline, 3 and 6 months of treatment

07

Study locations

5 sites
  • Centro de Investigación y Avances Médicos Especializados
    Cancún, Quintana Roo 77506, Mexico
  • Mérida Investigación Clínica
    Merida, Yucatan 97125, Mexico
  • Centro de Investigación Médica Aguascalientes
    Aguascalientes, 20116, Mexico
  • Oaxaca Site Management Organization SC.
    Oaxaca, 68000, Mexico
  • Oncológico Potosino
    San Luis Potosí, 78250, Mexico
08

References and documents

Publications

  • American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002. PubMed 31862745 ↗
  • Cahn A, Raz I, Kleinman Y, Balicer R, Hoshen M, Lieberman N, Brenig N, Del Prato S, Cefalu WT. Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. Diabetes Care. 2015 Dec;38(12):2293-300. doi: 10.2337/dc15-0187. Epub 2015 Oct 30. PubMed 26519337 ↗
  • Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004 May;27(5):1218-24. doi: 10.2337/diacare.27.5.1218. PubMed 15111553 ↗
  • Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005 May;118 Suppl 5A:27S-34S. doi: 10.1016/j.amjmed.2005.04.012. PubMed 15850551 ↗
  • Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? Diabetes Obes Metab. 2018 Jun;20(6):1337-1341. doi: 10.1111/dom.13243. Epub 2018 Mar 11. PubMed 29405543 ↗
  • Orozco-Beltran D, Mata-Cases M, Artola S, Conthe P, Mediavilla J, Miranda C. [Adherence of Type 2 Diabetes Mellitus approach: Current situation and possible solutions]. Aten Primaria. 2016 Jun-Jul;48(6):406-20. doi: 10.1016/j.aprim.2015.09.001. Epub 2016 Jan 13. Spanish. PubMed 26775266 ↗
  • Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, Garvey WT, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Perreault L, Rosenblit PD, Samson S, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 Jan;26(1):107-139. doi: 10.4158/CS-2019-0472. No abstract available. PubMed 32022600 ↗
  • Lukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014 May;16(5):403-9. doi: 10.1111/dom.12229. Epub 2013 Dec 2. PubMed 24199686 ↗
  • Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016 Jun 7;164(11):740-51. doi: 10.7326/M15-2650. Epub 2016 Apr 19. PubMed 27088241 ↗
  • Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT; MASTERMIND Consortium. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. 2018 Sep;41(9):1844-1853. doi: 10.2337/dc18-0344. Epub 2018 Aug 2. PubMed 30072404 ↗
  • Bianchi C, Daniele G, Dardano A, Miccoli R, Del Prato S. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs. 2017 Mar;77(3):247-264. doi: 10.1007/s40265-017-0694-4. PubMed 28155046 ↗
  • U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995 Nov;44(11):1249-58. PubMed 7589820 ↗
  • Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998 Apr;15(4):290-6. doi: 10.1002/(SICI)1096-9136(199804)15:43.0.CO;2-M. PubMed 9585393 ↗
  • Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012 Jan;29(1):26-40. doi: 10.1007/s12325-011-0096-z. Epub 2012 Jan 12. PubMed 22246944 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Mar 2024, 11 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 12, 2021
StartActual
Mar 21, 2023
Primary completionActual
Mar 15, 2024
CompletionActual
May 15, 2024
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04841096
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
Mar 21, 2023
Primary completion
Mar 15, 2024
Completion
May 15, 2024
Last update
Jun 10, 2025

Study contacts

Salvador Pérez Jaime, M.D
principal investigator · Centro de Investigación Médica Aguascalientes (Red OSMO)
Juan A Becerra Hernández, M.D
principal investigator · Centro de Investigación y Avances Médicos Especializados (Red OSMO)
Ana L Flores Barranco, M.D
principal investigator · Oaxaca Site Management Organization SC. (Red OSMOS)
Abraham S Álvarez, M.D
principal investigator · Oncológico Potosino (Red OSMO)
Victor C Bohórquez López, M.D
principal investigator · Mérida Investigación Clínica (Red OSMO)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glimepiride · Vildagliptin · Metformin

Start the discussion